Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China

被引：0

作者：

Song, Yuqin ^{[1
]}

Ying, Zhitao ^{[1
]}

Yang, Haiyan ^{[2
]}

Guo, Ye ^{[3
]}

Li, Wenyu ^{[4
]}

Zou, Dehui ^{[5
,6
,7
]}

Wu, Jianqiu ^{[8
]}

Yang, Su ^{[9
]}

Zhang, Pian ^{[9
]}

Ma, Meilin ^{[9
]}

Zhou, Zisong ^{[9
]}

Zheng, Hongxia ^{[9
]}

Zhu, Jun ^{[1
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China

[2] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Dept Med Oncol, Hangzhou, Peoples R China

[3] Shanghai Dongfang Hosp, Tongji Univ, Dept Med Oncol, Shanghai, Peoples R China

[4] Guangdong Acad Sci, Dept Lymphoma, Guangdong Provincial Peoples Hosp, Guangzhou, Guangdong, Peoples R China

[5] Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Blood Dis Hosp, Tianjin, Peoples R China

[6] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China

[7] Peking Union Med Coll, Tianjin, Peoples R China

[8] Affiliated Hosp Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Jiangsu Red Cross Canc Ctr, Nanjing, Peoples R China

[9] JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-150085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2434

引用

页数：4

共 50 条

[31] Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study
Phillips, Tycel
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collin, Graham P.
Lopez-Jimenez, Javier
Reddy, Nishitha
Mengarelli, Andrea
Musuraca, Gerardo
Sheehy, Oonagh
Xu, Weiming
Azoulay, Michel
Ghalie, Richard G.
Zinzani, Pier Luigi
Zelenetz, Andrew D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S388
[32] Polatuzumab vedotin plus obinutuzumab plus venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
Bannerji, Rajat
Yuen, Sam
Phillips, Tycel Jovelle
Arthur, Christopher
Isufi, Iris
Marlton, Paula
Seymour, John Francis
Corradini, Paolo
Molinari, Annalia
Gritti, Giuseppe
Emmons, Robert
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Flowers, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.
Zelenetz, Andrew David
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collins, Graham P.
Lopez-Jimenez, Javier
Reddy, Nishitha
Mengarelli, Andrea
Phillips, Tycel Jovelle
Musuraca, Gerardo
Sheehy, Oonagh
Li, Joanne
Xu, Weiming
Azoulay, Michel Meyer
Ghalie, Richard
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
Schuster, Stephen J.
Dickinson, Michael J.
Dreyling, Martin H.
Martinez, Joaquin
Kolstad, Arne
Butler, Jason Paul
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Abdelhady, Ahmed M.
Zia, Aiesha
Morisse, Mony Chenda
Fowler, Nathan Hale
Thieblemont, Catherine
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
Munoz, Javier
Reagan, Patrick M.
Goy, Andre
Miklos, David B.
Zheng, Dan
Fang, Xiang
Shen, Rhine R.
Siddiqi, Rubina
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael
ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
[36] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
[37] Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China
Ying, Zhitao
Yang, Haiyan
Guo, Ye
Li, Wenyu
Zou, Dehui
Zhou, Daobin
Wang, Zhao
Zhang, Mingzhi
Wu, Jianqiu
Liu, Hui
Zhang, Pian
Yang, Su
Zhou, Zisong
Zheng, Hongxia
Song, Yuqin
Zhu, Jun
CANCER MEDICINE, 2021, 10 (03): : 999 - 1011
[38] Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Pagel, John
Morschhauser, Franck
Herve, Tilly
Chaidos, Aristeidis
Phillips, Tycel
Ribrag, Vincent
Campbell, Phillip
Fruchart, Christophe
Jurczak, Wojciech
McKay, Pamela
Opat, Stephen
Radford, John
McDonald, Alice
Howell, Haley
Newberry, Kate
Woodruff, Mark
Clawson, Alicia
Larus, John
Blakemore, Stephen
Miao, Harry
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S279
[39] PACEBOM in relapsed/refractory (R/R) lymphoma in the rituximab (R) era
Tamjid, B.
McKendrick, J.
Doig, R.
Hosking, P.
James, P.
Anthony, S.
Hawkes, E.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S655 - S655
[40] PACEBOM IN RELAPSED/REFRACTORY (R/R) LYMPHOMA IN THE RITUXIMAB (R) ERA
Tamjid, B.
McKendrick, J.
Schwarer, A.
Doig, R.
James, P.
Hosking, P.
Hawkes, E. A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 65 - 65

← 1 2 3 4 5 →